FDA Investigating Serious Bleeding Events With Dabigatran

December 7, 2011

Share:

The U.S. Food and Drug Administration (FDA) is evaluating post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate). Pradaxa is a blood thinning (anticoagulant) medication used to reduce the risk of stroke in patients with non-valvular atrial fibrillation.

Read the FDA's drug safety alert.